Jubilant Pharma appoints GP Singh as CEO

Jubilant Life Sciences Ltd (JLL) has announced that GP Singh has been appointed as CEO of Jubilant Pharma Ltd, a wholly-owned subsidiary of JLL. Singh, who will be based in the US, will have overall responsibility for the operations under Jubilant Pharma and will report to the Jubilant Pharma board.
 
Prior to Jubilant, Singh had served as president of Sun Pharmaceuticals, USA. He has worked extensively both in India and in the US in various leadership roles pertaining to strategy, M&A, commercial and operations.
 
Earlier, Jubilant had appointed Pramod Yadav and Rajesh Srivastava as co-CEOs of the Life Science Ingredients business of JLL. This is pursuant to the previously announced management consolidation of pharmaceuticals and life science ingredients segment thereby harnessing the true potential in each businesses to aid focused faster growth for the company.